Track topics on Twitter Track topics that are important to you
In a lawsuit filed by Express Diagnostics, the company seeks damages from Premier Biotech for alleged illegal transfer of intellectual property, misrepresentation, and failure to pay for product, among other claimed contract violations.
Blue Earth, Minn. (PRWEB) August 01, 2017
Express Diagnostics Int’l, Inc. (EDI), FDA-registered and ISO 13485:2003-certified manufacturer of DrugCheck® and private-label drug testing devices, has filed a breach of contract complaint against Premier Biotech, Inc., and its owner, Todd Bailey. The lawsuit, filed in Faribault County, Minn. (Fifth Judicial Court, Case # 22-CV-17-322), alleges multiple instances of Premier Biotech breaching EDI contracts. Allegations include illegal transfer of intellectual property, misrepresentation, and failure to pay for product, all causing irreparable financial harm to EDI.
According to court documents, pursuant to a 2012 agreement, EDI granted Premier the limited exclusive right to sell and distribute products that incorporate EDI’s patents, technologies, innovations, designs, and other intellectual property. The contract states that Premier “shall not have or claim to have any intellectual property rights of any kind in the intellectual property” and also prohibits Premier from reverse engineering any of EDI’s intellectual property.
Specific allegations of the lawsuit include:
“Express Diagnostics has a responsibility to its stakeholders, customers, and employees to protect its intellectual property and R&D investments,” says Paul Johnson, president and CEO of Express Diagnostics Int’l. "According to court documents, Premier Biotech and Todd Bailey have violated their contractual duties. The lawsuit alleges that Premier Biotech continues to infringe on our intellectual property and, in addition, walked away from contractual obligations owing past due invoices for product totaling hundreds of thousands of dollars.”
Attached with the suit are multiple exhibits supporting EDI’s complaint, including contracts outlining terms both EDI and Premier agreed to but that the defendant is alleged to have subsequently violated.
About Express Diagnostics Int’l, Inc.
Express Diagnostics Int’l (EDI), FDA-registered and ISO 13485:2003-certified manufacturer of DrugCheck® onsite drugs of abuse screening devices, has grown from five employees to 100 since its founding in Blue Earth, Minn., in 2004. EDI has been named three times to Inc. magazine’s Inc. 5000 list of fastest-growing companies in the U.S. The company’s combination of toxicology, manufacturing, development, and marketing expertise has helped position Express Diagnostics Int’l as a world leader in rapid drug testing. Learn more at drugcheck.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14559467.htmNEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...